在晚期胸膜癌中使用伦瓦提尼布长期稳定疾病:一个病例报告
Eitetsu Koh1, Yasuo Sekine1, Tadao Nakazawa2
1Department of Thoracic Surgery, Tokyo Women's Medical University Yachiyo Medical Center, Chiba, Japan.
Rare tumors
|January 9, 2026
概括
伦瓦提尼布是一种多酶抑制剂,在患有晚期胸腺癌的患者中,证明了长时间的疾病稳定. 由于潜在的风险,仔细的肺部监测至关重要,特别是在胸部辐射后.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 无法切除的胸膜癌具有有限的治疗选择.
- 长期的真实世界数据在胸腺癌中的伦瓦提尼布很少.
研究的目的:
- 报告一个用lenvatinib治疗的晚期胸膜状细胞癌病例.
- 为了突出lenvatinib在现实环境中的疗效和毒性概况.
主要方法:
- 一名72岁的女性患有Masaoka阶段IVb胸腺状细胞癌,接受了lenvatinib治疗.
- 由于包括高血压,血和甲状腺功能低下在内的不良事件,因此调整了剂量.
主要成果:
- 患者在降低剂量的伦瓦提尼布治疗下实现了23个月的疾病稳定.
- 突然死亡发生,死后成像显示间歇性肺炎恶化.
结论:
- 伦瓦提尼布可以在晚期胸膜癌中实现长时间的疾病控制,即使剂量减少.
- 接受伦瓦提尼布治疗的患者,特别是有胸部辐射病史的患者,密切监测肺部是必不可少的.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K